Abstract
A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have